Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity

Table 1 Statistics of period and amplitude of the oscillation of MOG-specific T cells and microglia in EAE

			Period (days)	Amplitude (%)				Period (days)	Amplitude (%)
EAE	Spleen	MOG-T _eff	5 ± 0.7	0.8 ± 0.2 *	EAE anti-CD20 therapy	Spleen	MOG-T _eff	6.7 ± 0.7	0.3 ± 0.1 *
	Spleen	MOG-T _reg	4.3 ± 0.9	0.14 ± 0.02 *		Spleen	MOG-T _reg	6.7 ± 2.7	0.06 ± 0.02 *
	CNS	MOG-T _eff	4 ± 1	3.3 ± 0.9		CNS	MOG-T _eff	3.0 ± 0.4	2.4 ± 1.4
		MOG-T _reg	2.3 ± 0.9	4.0 ± 0.9 ***			MOG-T _reg	3.3 ± 0.7	0.5 ± 0.2 ***
		Microglia (activated)	8	60 ± 7			Microglia (activated)	--	57 ± 9
			Period (days)	Amplitude (cell num)				Period (days)	Amplitude (cell num)
Model EAE	Spleen	MOG-T _eff	5.2 ± 0.2 *	2254 ± 128 ***	Model EAE anti-CD20 therapy	Spleen	MOG-T _eff	6.5 ± 0.5 *	816 ± 18 ***
Model EAE	Spleen	MOG-T _reg	4.9 ± 0.2	552 ± 26 ***	Model EAE anti-CD20 therapy	Spleen	MOG-T _reg	5.5 ± 0.4	429 ± 10 ***

Period and amplitude of the peaks of active MOG-T_eff , MOG-T_reg and activated microglia in secondary lymphoid organs (spleen) and the CNS in animals developing EAE (as described in Figure 2), in model simulations (as described in Figure 4) and animals with EAE and treated with anti-CD20 therapy (as described in Figure 6). Amplitudes of MOG-specific T cells and activated microglia are shown as percentages to the CD4⁺ population and total microglia population, respectively; amplitudes in model simulations are expressed as cell number values. Data is shown as the mean ± SEM, statistical significance are between EAE versus EAE anti-CD20 therapy; sig. (*) p < 0.05, (***) p < 0.0001 (paired T test).

ISSN: 1752-0509